ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year delays in access to new antibiotics were common even in high income countries (19 Aug 2021 newsletter with YouTube discussion). But as we'll learn today, that analysis considers only one possible facet of "lack of access." In an instructive new paper, Baraldi, Ardal, Aho, Popescu, and Melaku have given us a powerful new analytical framework showing that there are at least six (6!) possible meanings of "Lack of Access" to antibiotics. Here are the links you need: The paper by Baraldi et al.: "The multifaceted nature of lack of access to antibiotics: types ofshortage and specific causes, consequences, and solutions" Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2024.11.012, 2024. A 2003 white paper summarizing indicators used as part of the Millennium Development Goals (MDGs), the predecessor to the current UN Sustainable Development Goals (SDGs): The white paper (the relevant text is on page 97) The MDG website The SDG website (the SDGs replaced the MDGs in 2015) So, what are the 6 variations on the idea of "Lack of Access"? The paper by Baraldi et al. focuses on 4 ways...
Dear All, Just released, the...
Dear All, The Global Leaders Group on Antimicrobial...
Latest Government Action
Dear All,BARDA has released a fascinating Sources Sought Notice (SSN) seeking data on antibacterials near, at, or beyond Phase 2. I've never seen one before, but an SSN is market research with which BARDA will "collect feedback from current and prospective antibiotic development partners" that will "serve as continued market research for potential future acquisitions and programs." While this might sound like just another pipeline review, we'll see in a moment that the query goes well beyond the relatively high-level pipeline reviews maintained by WHO (see the Bugs & Drugs webpage). Here is the link to the SSN along with its title, lightly broken up for ease of reading:SSN No.: BARDA-CBRN-11042024"Antimicrobial Resistance Project BioShield:"BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections"Caused by Drug-Resistant Bacteria or Biothreat Pathogens."The mention in the title of the SSN of "Project BioShield" is our further clue that this is part of BARDA's goal of having at least one MCM for all CBRN threats (translation: one Medical Counter-Measure for all Chemical, Biological, Radiological, and Nuclear threats) as part of their 2022-2026 Strategic Plan. To follow this in more detail, see the 4 Jun 2022 newsletter for more on BARDA's strategic plan and the 12 Nov...
Dear All, Greetings from Porto...
Dear All,During the GLG AMR...
Dear All,Well, ECCMID 2024 (Barcelona)...
Dear All (moderately wonkish, so...
R&D Insight
Dear All,As has been discussed...
Dear All, Committing serial email...
This newsletter is the first...
Dear All: You are doubtless...
Dear All,If there is a...
Dear All (lots and lots...
Dear All,A view from Cambodia:...
Dear All: EU's IMI (Innovative...
Can you help?
Dear All,I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City...
Dear All, Heads up! Having...
Note: Be sure to take...
Update on 11 October 2023: The...
Dear All,Along with more than...
Dear All (and with thanks to...
Dear All, Two items for...
Dear All, Three things today......
Dear All, Greetings from ECCMID...
Dear All,A key theme of...
Dear All,Following hard on the...
Dear All, A short one...
Dear All, We are swimming...
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
AMR Fireside Chats
1/18 videos
1
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
2
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
3
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
4
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
5
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
6
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
7
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
8
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
9
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
10
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
11
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
12
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
13
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
14
Episode 5 w/ Christine Årdal - AMR Fireside Chat
43:44
15
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
16
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
17
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
18
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
Dear All (wonkish alert: coffee up, settle in, and read the reports!), As you will recall, WHO’s most current pipeline review found that globally we
Read More →
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
Dear All (wonkish note alert — refresh your coffee before proceeding — with thanks to Kevin Outterson for co-authoring this note!), The intertwined questions of
Read More →
Developing systemic & inhaled antibiotics for lung infections
Dear All: I missed it personally, but by all reports the session on 3 June 2017 at ASM Microbe entitled “Development of New Drugs and
Read More →
FDA analysis of 40-years of antibacterial development: Dheman et al.
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in which FDA analyzes trends in
Read More →
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
Dear All (detailed and wonkish note alert … lots of thinking out loud … get some coffee and settle in!), I wrote previously (link) about
Read More →
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress
Read More →
The 6 meanings of “Lack of Access”
Dear All, We often talk about the problem of lack of access to new antibiotics. In late 2021, for example, we explored data showing that multi-year
Read More →
Public meeting on the LPAD Pathway: Post-meeting thoughts (wonkish)
Long and wonkish note alert — please refresh your coffee before you start reading! Dear All: I was able to attend and speak at the
Read More →
Developing antibiotics for children: There are no easy answers
Aside: If you’ve enjoyed the prior discussions of movies to inspire antibiotic R&D and very apropos given the theme of today’s newsletter, please check out the
Read More →
Modeling the value of an effective antibiotic — Megiddo et al.
Dear All: I have previously written about the challenge of applying health technology assessment (HTA) to estimate the monetary value of an effective antibiotic: To my knowledge,
Read More →
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
Dear All (wonkish note alert … top-up your coffee and settle in!), Today we have a tour of a recent paper in Clinical Infectious Diseases
Read More →
COVID-19 and the Long-Term Trajectory of AMR Efforts: Wellcome Trust Deep Dive
Dear All (Wonkish alert! Coffee-up!), Today we have something special: A deep-dive into the future trajectory of AMR-related work developed by Wellcome Trust. The newly
Read More →
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
Summaries
Notes: Newsflash ... BARDA have...
Aside: If you've enjoyed the...
Dear All,See also this related...
Dear All (and with thanks...
Dear All (Wonkish alert! Coffee-up!),Today...